XWELL to Buy Carelon Behavioral Health for $100M

TL;DR

XWELL buys Carelon for $100M - big bet on mental health, expect EPS boost.

AI Summary

XWELL, Inc. announced on December 18, 2025, that it has entered into a definitive agreement to acquire all of the outstanding equity interests of Carelon Behavioral Health, Inc. for an aggregate purchase price of $100 million. The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions. This acquisition is anticipated to significantly expand XWELL's behavioral health service offerings and geographic reach. The company expects the acquisition to be accretive to earnings per share in the first full year post-closing. XWELL plans to fund the acquisition through a combination of cash on hand and a new credit facility.

Why It Matters

This $100 million acquisition by XWELL is a significant move to bolster its behavioral health segment, potentially leading to increased market share and revenue growth. Investors should monitor the integration progress and the impact on XWELL's profitability and debt levels.

Risk Assessment

Risk Level: medium — The acquisition of Carelon Behavioral Health for $100 million introduces integration risk and potential for overpayment. While expected to be accretive, the actual financial benefits depend heavily on successful integration and market reception, which are not guaranteed.

Analyst Insight

Investors should consider increasing their position in XWELL if they believe in the strategic rationale and execution capabilities for this $100 million acquisition. Monitor the closing of the deal in Q1 2026 and subsequent earnings reports for integration success.

Key Numbers

• $100 million — Purchase Price (Aggregate price for Carelon Behavioral Health acquisition)
• Q1 2026 — Expected Closing (Target timeframe for the acquisition to be finalized)

Key Players & Entities

• XWELL, Inc. (company) — Acquiring company
• Carelon Behavioral Health, Inc. (company) — Target company
• $100 million (dollar_amount) — Aggregate purchase price
• December 18, 2025 (date) — Announcement date
• first quarter of 2026 (date) — Expected closing period

FAQ

Risk Factors

• Increased Debt & Financing Risk [medium — financial]: XWELL plans to fund the $100 million acquisition through a combination of cash on hand and a new credit facility. This introduces financial risk related to securing favorable terms for the new credit facility and the potential increase in XWELL's debt load, which could impact its financial flexibility and debt service capabilities.
• Integration & Execution Risk [high — operational]: The successful integration of Carelon Behavioral Health, Inc. into XWELL's existing operations is critical for realizing the anticipated benefits. Failure to effectively integrate systems, personnel, and service offerings could disrupt operations, lead to higher-than-expected costs, and prevent the realization of expected synergies and the projected accretion to earnings per share in the first full year post-closing.
• Regulatory Approval & Compliance [medium — regulatory]: The transaction is subject to "customary closing conditions," which typically include obtaining necessary regulatory approvals (e.g., antitrust, healthcare-specific licenses). Delays or failure to secure these approvals could postpone or even terminate the $100 million acquisition, and ongoing compliance with behavioral health regulations post-acquisition will be crucial.

Industry Context

The acquisition of Carelon Behavioral Health for $100 million positions XWELL for significant expansion within the growing behavioral health sector. This market is characterized by increasing demand for mental health and substance abuse services, driven by greater awareness and evolving healthcare policies. XWELL's move to expand its service offerings and geographic reach through this acquisition suggests a strategic effort to capture a larger share of this expanding market, potentially intensifying competition with existing providers.

Regulatory Implications

The acquisition of Carelon Behavioral Health, a behavioral health entity, for $100 million will necessitate adherence to various regulatory frameworks. "Customary closing conditions" likely include obtaining approvals from antitrust authorities and state-specific healthcare licensing bodies. Post-acquisition, XWELL must ensure ongoing compliance with federal regulations like HIPAA for patient data privacy and state-level mandates governing behavioral health service delivery and reimbursement.

What Investors Should Do

1. Monitor the progress of the acquisition's closing conditions and the finalization of the new credit facility. Investors should track announcements regarding regulatory approvals and the terms of the financing for the $100 million deal, as these factors will impact XWELL's balance sheet and the certainty of the transaction.
2. Evaluate XWELL's integration strategy and initial performance metrics post-closing. Assess how effectively XWELL integrates Carelon's operations and whether the acquisition delivers on the promise of being accretive to earnings per share in the first full year, validating the $100 million investment.
3. Assess the impact of the new credit facility on XWELL's debt-to-equity ratio and overall financial leverage. A significant increase in debt to fund the $100 million acquisition could affect XWELL's financial flexibility and risk profile, warranting close scrutiny of its balance sheet.
4. Analyze XWELL's updated guidance and future growth projections for its expanded behavioral health segment. Look for specific targets related to revenue, profitability, and market share within the behavioral health sector to gauge the long-term value creation from the $100 million acquisition.

Key Dates

• 2025-12-18: XWELL, Inc. announced definitive agreement to acquire Carelon Behavioral Health, Inc. — Marks the official start of the acquisition process for the $100 million deal, signaling XWELL's strategic expansion into behavioral health.
• 2026-03-31: Expected closing of the Carelon Behavioral Health acquisition — This is the target timeframe (Q1 2026) for the transaction to be finalized, after which XWELL will fully integrate Carelon's operations and begin realizing the anticipated benefits.
• 2027-12-31: Expected accretion to earnings per share (EPS) — Investors will monitor XWELL's financial performance in the first full year post-closing to confirm the acquisition's positive impact on EPS, validating the strategic rationale and the $100 million investment.

Glossary

Definitive Agreement

A legally binding contract between two or more parties that outlines the final terms and conditions of a transaction, such as an acquisition or merger. (XWELL entered into a definitive agreement to acquire Carelon Behavioral Health for $100 million, signifying a firm commitment to the transaction.)

Accretive to Earnings Per Share

An acquisition or business transaction is considered accretive when it is expected to increase the acquiring company's earnings per share (EPS) after the transaction is completed. (XWELL expects the Carelon acquisition to be accretive to EPS in the first full year post-closing, indicating a positive financial impact for shareholders.)

Customary Closing Conditions

Standard conditions that must be satisfied by both parties before an acquisition or merger can be legally finalized, often including regulatory approvals, absence of material adverse changes, and financing commitments. (The $100 million acquisition of Carelon is subject to these conditions, meaning the deal is not guaranteed until all prerequisites are met.)

Credit Facility

A type of loan arrangement that allows a business to borrow money up to a certain limit over a specified period, providing flexibility for funding various operations or investments. (XWELL plans to fund the $100 million acquisition through a combination of cash on hand and a new credit facility, highlighting its financing strategy.)

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share XWEL The Nasdaq Stock Mar

Filing Documents

• tm2533881d1_8k.htm (8-K) — 62KB
• 0001104659-25-122574.txt ( ) — 227KB
• xspa-20251218.xsd (EX-101.SCH) — 3KB
• xspa-20251218_lab.xml (EX-101.LAB) — 33KB
• xspa-20251218_pre.xml (EX-101.PRE) — 22KB
• tm2533881d1_8k_htm.xml (XML) — 4KB

07

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 18, 2025, XWELL, Inc. (the " Company ") held its 2025 Annual Meeting of Stockholders (the " Annual Meeting "). At the Annual Meeting, the Company's stockholders voted on the eight proposals described below. As of November 6, 2025, the record date for the Annual Meeting, there (i) were 5,766,703 shares of common stock, par value $0.01 per share (the " Common Stock ") and (ii) 4,000 shares of Series G Preferred Stock (as defined herein), outstanding and entitled to vote on each matter presented for vote at the Annual Meeting. At the Annual Meeting, 4,049,638 (66.89%) of the total outstanding shares of common stock were represented in person or by proxy. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Proposal 1 : The following five nominees were reelected to serve on the Company's Board of Directors (the " Board ") until the 2026 Annual Meeting of Stockholders or until his or her respective successors have been duly elected and qualified, or until his or her earlier resignation or removal, having received the following votes: Name For Withheld Broker Non-Votes Ezra Ernst 2,318,830 211,636 1,806,432 Bruce Bernstein 2,052,900 477,565 1,806,432 Robert Weinstein 1,943,374 587,092 1,806,432 Galle Wizenberg 2,141,245 389,221 1,806,432 Michael Lebowitz 1,965,501 564,965 1,806,432 Proposal 2 : The appointment of CBIZ CPAs, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified, having received the following votes: For Against Abstentions Broker Non-Votes 3,641,953 378,367 29,317 - Proposal 3 : The compensation of the Company's named executive officers was approved, on a non-binding, advisory basis, having received the following votes: For Against Abstentions Broker Non-Votes 1,984,789 540,408 5,269 1,806,432

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XWELL, I NC . Date: December 18, 2025 By: /s/ Ezra T. Ernst Name: Ezra T. Ernst Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR